Download PDF
Klin Monbl Augenheilkd 2022; 239(04): 527-530
DOI: 10.1055/a-1766-7035
Der interessante Fall

Decrease in Visual Acuity in a 77-Year-old Woman with Age-Related Macular Degeneration after a SARS-CoV-2 Infection Treated with Hydroxychloroquine

Reduktion der Sehschärfe einer 77-jährigen Patientin mit altersbezogener Makuladegeneration nach Behandlung einer SARS-CoV-2-Infektion mittels Hydroxychloroquin
Anahita Bajka
1   Ophthalmology, University Hospital of Zürich, Zürich, Switzerland
,
Mario Toro 
1   Ophthalmology, University Hospital of Zürich, Zürich, Switzerland
,
Christoph Kniestedt
2   Ophthalmology, Talacker Augen Zentrum Zürich (TAZZ), Zürich, Switzerland
,
Sandrine Zweifel
1   Ophthalmology, University Hospital of Zürich, Zürich, Switzerland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Introduction

To date, hydroxychloroquine (HCQ) is a well-established antimalarial and immunomodulatory drug used as a treatment for several autoimmune and infectious diseases including rheumatoid arthritis, lupus erythematosus, and malaria [1], [2]. Recently, HCQ has been used as pre-/postexposure prophylaxis and treatment for the coronavirus disease 2019 (COVID-19) [3], [4], [5], [6]. However, despite the potential antiviral effects and its anti-inflammatory profile, the results based on clinical studies regarding HCQ as a treatment for SARS-CoV-2 are contradictory, and main concerns exist for its efficacy and safety profile [1], [2], [3], [7], [8]. In addition, studies have shown that the benefits of treating SARS-CoV-2 patients are limited and do not seem to outweigh side effects [2], [3], [5], [7]. Thus, the World Health Organization (WHO) no longer recommends HCQ to prevent or treat patients with SARS-CoV-2 [9]. Among common side effects, HCQ can cause gastrointestinal discomfort, headache, and dizziness, but also more severe side effects such as cardiotoxicity and ocular toxicity [1], [3], [6]. Regarding ocular toxicity, manifestations can be corneal deposits, ciliary body dysfunction, posterior subcapsular lens opacity, and retinopathy [10], [11]. Symptoms of an HCQ retinopathy can include blurred vision, loss of night vision, and partial central or peripheral loss of vision [10].

In the last decade, spectral-domain and swept-source optical coherence tomography (SD-OCT and SS-OCT) have been established as noninvasive imaging technologies to assess structural changes of the retina in several ocular diseases and can help to assess the progression of an HCQ retinopathy [12], [13], [14], [15], [16], [17].

As HCQ can deposit in melanin-containing tissues such as the RPE (retinal pigment epithelium), the function of the RPE gets disrupted, leading to a reduction of lysosomal degradation of shed outer segments. With the progression of the disease, a degeneration of RPE as well as a disruption of the ellipsoid zone can result in complete atrophy of the RPE and outer retina (cRORA) [1], [18].

These changes are visible in SD-OCT. The disruption of the ellipsoid zone and the loss of the outer nuclear layer (ONL) [11], [19] cause a collapse of the parafoveal retina, which can lead to a “flying saucer” appearance of the fovea [20]. These structural changes in the outer retina usually correlate with functional changes shown in multifocal electroretinograms (mERGs) and changes in the visual field [10], [11].

Geographic atrophy (GA), as a subset manifestation of cRORA, can appear as a sign of advanced age-related macular degeneration (AMD), causing irreversible vision loss without any treatment possibility known to date. The growth rate of GA plays a key role in determining the prognosis of a patient with AMD. Regarding the progression of GA, previous studies have shown that outer retinal tubulations (ORTs) could be associated with a slower progression of GA.

Autofluorescence (AF) or scanning laser ophthalmoscopy (SLO) en face images are used to measure GA at baseline and at each follow-up visit to determine a growth rate per year or more years. The literature describes growth rates of GA between 1.78 and 6.4 mm2 over 5 years and growth rates of 1.52, 1.61, and 2.2 mm2 per year [21], [22].

In this case, we aimed to present a case of a 77-year-old woman with a diagnosis of advanced dry AMD who experienced a drop in her visual acuity (VA) after she had a SARS-CoV-2 infection, and was treated with HCQ. GA in SLO en face OCT images were used to measure the progression of GA within 7 years (follow-up).



Publication History

Received: 27 September 2021

Accepted: 06 February 2022

Article published online:
26 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16: 155-166
    CrossrefPubMedGoogle Scholar
  • 2 Grygiel-Górniak B. Antimalarial drugs-are they beneficial in rheumatic and viral diseases? – Considerations in COVID-19 pandemic. Clin Rheumatol 2022; 41: 1-18 DOI: 10.1007/s10067-021-05805-5.
    CrossrefPubMedGoogle Scholar
  • 3 Martins-Filho PR, Ferreira LC, Heimfarth L. et al. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am 2021; 2: 100062 DOI: 10.1016/j.lana.2021.100062.
    CrossrefPubMedGoogle Scholar
  • 4 Zhanel GG, Zhanel MA, Boreskie KF. et al. Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. Can J Infect Dis Med Microbiol 2021; 2021: 5942366
    CrossrefPubMedGoogle Scholar
  • 5 Ruamviboonsuk P, Lai TYY, Chang A. et al. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. Asia Pac J Ophthalmol (Phila) 2020; 9: 85-87
    CrossrefPubMedGoogle Scholar
  • 6 Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 2020; 75: 1667-1670
    CrossrefPubMedGoogle Scholar
  • 7 Cavalcanti AB, Zampieri FG, Rosa RG. et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020; 383: 2041-2052
    CrossrefPubMedGoogle Scholar
  • 8 Hache G, Rolain JM, Gautret P. et al. Combination of Hydroxychloroquine Plus Azithromycin as Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microb Drug Resist 2021; 27: 281-290
    CrossrefPubMedGoogle Scholar
  • 9 World Health Organization (WHO). Coronavirus disease (COVID-19): Hydroxychloroquine; 2021. Accessed April 30, 2021 at: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-hydroxychloroquine
    PubMedGoogle Scholar
  • 10 Stokkermans TJ, Goyal A, Bansal P. et al. Chloroquine and Hydroxychloroquine Toxicity. In: StatPearls. Treasure Island (FL): 2021. Accessed May 7, 2021 at: https://www.ncbi.nlm.nih.gov/books/NBK537086/
    Google Scholar
  • 11 Ozawa H, Ueno S, Ohno-Tanaka A. et al. Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment. Jpn J Ophthalmol 2021; 65: 472-481
    CrossrefPubMedGoogle Scholar
  • 12 Longo A, Avitabile T, Uva MG. et al. Morphology of the optic nerve head in glaucomatous eyes with visual field defects in superior or inferior hemifield. Eur J Ophthalmol 2018; 28: 175-181
    CrossrefPubMedGoogle Scholar
  • 13 Longo A, Avitabile T, Uva MG. et al. Optic nerve head in central retinal vein occlusion by spectral-domain OCT. Eur J Ophthalmol 2017; 27: 485-490
    CrossrefPubMedGoogle Scholar
  • 14 Reibaldi M, Parravano M, Varano M. et al. Foveal microstructure and functional parameters in lamellar macular hole. Am J Ophthalmol 2012; 154: 974-980.e1
    CrossrefPubMedGoogle Scholar
  • 15 Reibaldi M, Uva MG, Avitabile T. et al. Intrasession reproducibility of RNFL thickness measurements using SD-OCT in eyes with keratoconus. Ophthalmic Surg Lasers Imaging 2012; 43 (6 Suppl.): S83-S89
    CrossrefPubMedGoogle Scholar
  • 16 Chisari CG, Toro MD, Cimino V. et al. Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. J Clin Med 2019; 8: 2022
    CrossrefPubMedGoogle Scholar
  • 17 Ceravolo I, Oliverio GW, Alibrandi A. et al. The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. Diagnostics (Basel) 2020; 10: 413
    CrossrefPubMedGoogle Scholar
  • 18 Bansal P, Goyal A, Cusick 4th A. et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med 2021; 53: 117-134
    CrossrefPubMedGoogle Scholar
  • 19 Casado A, López-de-Eguileta A, Fonseca S. et al. Outer Nuclear Layer Damage for Detection of Early Retinal Toxicity of Hydroxychloroquine. Biomedicines 2020; 8: 54 DOI: 10.3390/biomedicines8030054.
    CrossrefPubMedGoogle Scholar
  • 20 Chen E, Brown DM, Benz MS. et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol 2010; 4: 1151-1158
    CrossrefPubMedGoogle Scholar
  • 21 Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol 2015; 9: 2159-2174
    CrossrefPubMedGoogle Scholar
  • 22 Klein R, Klein BEK, Linton KLP. Prevalence of Age-related Maculopathy: The Beaver Dam Eye Study. Ophthalmology 2020; 127 (4S): S122-S132
    CrossrefPubMedGoogle Scholar
  • 23 Hariri A, Nittala MG, Sadda SR. Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration. Ophthalmology 2015; 122: 407-413
    CrossrefPubMedGoogle Scholar
  • 24 Haensli C, Sugiura Y, Freund KB. et al. Correlation of Outer Retinal Tubulations and Choriocapillaris Flow Signal Deficits surrounding Geographic Atrophy. Retina 2021; 41: 1940-1947
    CrossrefPubMedGoogle Scholar
  • 25 Nicolo M, Ferro Desideri L, Bassetti M. et al. Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. Int Ophthalmol 2021; 41: 719-725
    CrossrefPubMedGoogle Scholar
  • 26 Al Adel F, Shoughy SS, Tabbara KF. Hydroxychloroquine dosing and toxicity: A real-world experience in Saudi Arabia of 63 patients. Saudi J Ophthalmol 2020; 34: 151-155
    CrossrefPubMedGoogle Scholar
  • 27 Wrzesinska D, Nowomiejska K, Nowakowska D. et al. Vertical and Horizontal M-Charts and Microperimetry for Assessment of the Visual Function in Patients after Vitrectomy with ILM Peeling due to Stage 4 Macular Hole. J Ophthalmol 2019; 2019: 4975973
    CrossrefPubMedGoogle Scholar
  • 28 Wrzesinska D, Nowomiejska K, Nowakowska D. et al. Secondary Vitrectomy with Internal Limiting Membrane Plug due to Persistent Full-Thickness Macular Hole OCT-Angiography and Microperimetry Features: Case Series. J Ophthalmol 2020; 2020: 2650873
    CrossrefPubMedGoogle Scholar
  • 29 Borowicz D, Nowomiejska K, Nowakowska D. et al. Functional and morphological results of treatment of macula-on and macula-off rhegmatogenous retinal detachment with pars plana vitrectomy and sulfur hexafluoride gas tamponade. BMC Ophthalmol 2019; 19: 118
    CrossrefPubMedGoogle Scholar